APOC3 and Thrombocytopenia: No patients developed thrombocytopenia during this 52-week study and thus, the previously noted thrombocytopenia was most likely an off-target effect of Volanesorsen and not caused by a loss of hepatic apoC-III secretion and/or its downstream effects.